Vitiligo strips the skin of its color in patches, and the search for a way to bring that color back has pushed researchers toward almost every kind of light, including the red and near-infrared wavelengths used in red light therapy. The honest picture is narrow: a handful of small studies on red laser light show real repigmentation in one specific type of vitiligo, while the broad consumer market for red light panels and masks has almost no direct evidence behind it. This review walks through what the science actually supports, where it falls apart, and how red light stacks up against the treatments dermatologists actually use.
What Vitiligo Is and Why Light Matters
Vitiligo is an autoimmune condition. The body's own immune system attacks and destroys melanocytes, the cells that make the pigment that gives skin its color. When enough melanocytes die in an area, that patch turns milky white. It affects roughly 1 in 100 people worldwide, and it shows up across every skin tone, though it stands out more on darker skin.
There are two main kinds. Non-segmental vitiligo is the common form. It tends to appear in symmetrical patches on both sides of the body and can spread over time. Segmental vitiligo is less common, usually shows up on one side of the body in a single band or section, and often stops spreading after a year or two. This distinction matters more than it sounds, because almost all of the red light evidence comes from segmental cases.
Light matters here because of where new pigment cells come from. When skin repigments, the color usually returns in tiny dots around hair follicles before spreading outward. That pattern happens because a reservoir of dormant melanocyte stem cells sits in the bulge region of each hair follicle. The goal of any light-based vitiligo treatment is to wake up those stem cells, push them to multiply, and guide them up to the surface where they can make pigment again.
How Red Light Is Supposed to Work
Red light therapy, also called photobiomodulation, uses red (around 630 to 660 nanometers) and near-infrared (around 810 to 850 nanometers) light. Unlike the ultraviolet light used in standard vitiligo phototherapy, these wavelengths carry no UV and do not burn or tan the skin. The light is absorbed by parts of the cell, mainly the mitochondria, and is thought to nudge cellular activity rather than damage tissue.
For vitiligo specifically, lab and clinical work points to a few proposed mechanisms. Red light appears to stimulate the migration and multiplication of melanocytes and their precursor cells, the melanoblasts. A 2019 mechanism review in Experimental Dermatology describes how photobiomodulation may mobilize melanocyte stem cells from the hair follicle, increase growth factors that pigment cells respond to, and promote their movement toward the surface of the skin. The same line of research has tied repigmentation to the Wnt/beta-catenin signaling pathway, which controls how stem cells differentiate into working melanocytes.
There is also a circulation angle. One controlled study of segmental vitiligo found that the affected patches had abnormal blood flow and a faulty response in the small skin nerves, and that red laser treatment appeared to normalize both. The authors argued the benefit came partly from fixing this microcirculation problem, not only from acting on pigment cells directly. This fits the segmental pattern, where nerve and blood-vessel abnormalities along a single body segment are thought to play a role in why the patches form where they do.
To understand why this could matter, it helps to know how pigment normally returns. Repigmentation is a two-step job. First, dormant melanocyte stem cells in the hair follicle have to wake up and divide. Then their offspring have to crawl outward and upward, reach the surface of the skin, and start producing melanin again. Red light is proposed to help at both steps: it may release growth factors from neighboring skin cells that act as a chemical signal for pigment cells, and it may directly encourage those cells to move and multiply. The lab work behind the He-Ne laser studies showed that light-treated skin cells released more of two specific growth factors, basic fibroblast growth factor and nerve growth factor, and that fluid from those treated cells made melanocytes grow faster in a dish.
The key word in all of this is "proposed." These mechanisms are plausible and supported by lab data, but a believable mechanism is not the same as proof that a device on your bathroom shelf will repaint your skin. Lab cells in a controlled dish behave nothing like an active autoimmune disease attacking living tissue, where the immune system can keep killing new pigment cells faster than light can coax them back. A mechanism tells you something is possible. Only a trial tells you it works.
What the Clinical Evidence Actually Shows
Here is the part that gets oversold. When marketers cite "60% repigmentation" for red light therapy and vitiligo, they are almost always pointing to one small study from 2003 using a specific medical laser, not a consumer LED panel. The evidence base is thin, old, and narrow.
The Helium-Neon Laser Studies
The strongest data comes from helium-neon (He-Ne) lasers, which emit a precise 632.8 nm red beam. A 2003 study in the Journal of Investigative Dermatology treated 30 patients with segmental-type vitiligo on the head and neck. Using 3.0 J/cm² delivered once or twice a week, the researchers reported that after an average of around 16 sessions, more than 50% repigmentation appeared in 60% of patients. A later controlled study in 2008 of 40 segmental vitiligo patients used the same wavelength and dose and reported the same headline figure: marked repigmentation (over 50%) in 60% of patients after roughly 17 sessions.
Those results are genuinely encouraging, but read the fine print. Both studies were small, with roughly 70 patients combined. Both used a focused medical laser, not a panel of LEDs. Both enrolled only segmental vitiligo on the head and neck, which is a small slice of all vitiligo. Neither was a large, blinded, placebo-controlled trial, and neither had a control group treated with sham light. So the "60%" number is real, but it describes a narrow procedure in a narrow patient group.
It also helps to know why segmental head-and-neck vitiligo was chosen. Those areas are densely covered in hair follicles, and the follicle is where the reservoir of dormant pigment stem cells lives. More follicles means more raw material for the light to work with. Vitiligo on hairless skin, like the backs of the hands or the lips, has far fewer of these reservoirs and responds poorly to almost every treatment, light included. So even within vitiligo, the laser data applies to the locations most likely to respond, which inflates how impressive the headline number looks if you assume it applies everywhere.
The Gap Between Lasers and Consumer Panels
Almost no controlled trials test the red light masks, wands, and full-body panels sold for home use against vitiligo. The wavelengths overlap with the He-Ne laser, which is why the marketing leans on those studies. But a coherent laser beam and a diffuse LED array deliver light very differently in terms of focus, intensity, and dose. Extrapolating from a 632.8 nm clinical laser to a $300 panel is a leap the evidence does not support.
Red Light as an Add-On
The more recent interest is in combining red light with treatments that already work. A 2026 case report described a 37-year-old man with non-segmental vitiligo on his arms and hands who had failed both topical therapy and 308 nm excimer light alone, then showed gradual repigmentation over about three months when 635 nm red light was added to the excimer treatment, with no side effects reported. That is a single patient. It hints at a possible role for red light as a helper rather than a standalone fix, but one case proves almost nothing on its own. Case reports are notorious for being published only when they turn out well, so they tell you what can happen, not how often it happens.
The logic behind combining them is reasonable. The excimer light targets the immune attack and stimulates pigment cells with UVB, while the red light might support the same pigment cells through a different, non-UV pathway. If that pans out in real trials, red light could earn a supporting role. But "could" is doing heavy lifting in that sentence, and the field is not there yet.
Honest Evidence Grading
| Use of red light for vitiligo | Best available evidence | Strength | Bottom line |
|---|---|---|---|
| He-Ne red laser (632.8 nm) for segmental vitiligo | 2 small clinical studies, ~70 patients total | Weak to moderate | Real repigmentation shown, but tiny and narrow |
| Consumer LED red light panels/masks | Essentially none specific to vitiligo | Very weak / absent | No direct trial support |
| Red light added to excimer or NB-UVB | Case reports, small pilots | Very weak | Promising idea, unproven |
| Red light for non-segmental vitiligo alone | Almost none | Very weak / absent | Not supported |
No large randomized controlled trial has confirmed long-term benefit, an optimal protocol, or durability of results for red light therapy in vitiligo. That is the single most important sentence in this article.
What "Dose" Even Means Here
A practical problem buried under the optimism is dosing. The laser studies used a tightly defined dose: 632.8 nm at 3.0 J/cm², delivered once or twice a week, with point-by-point treatment of the patches. A consumer panel does not let you reproduce that. Panel marketing lists "irradiance" and total watts, but the dose that actually reaches a patch depends on the distance from the device, the time exposed, and how the diffuse light spreads, none of which a home user can measure precisely. So even if the laser dose were the right target, there is no reliable way to hit it with a panel, and no study has worked out what a panel dose should be for vitiligo in the first place. When someone claims a home device "matches" the studies, ask how they know the dose at the skin.
How Red Light Compares to Proven Treatments
Vitiligo does have treatments with strong evidence. They just are not red light.
Narrowband UVB (NB-UVB)
Narrowband ultraviolet B phototherapy is the most widely used and best-supported light treatment for widespread vitiligo. It uses UV light around 311 nm to both calm the immune attack and stimulate pigment cells. It works on both segmental and non-segmental disease and remains a first-choice option for people with extensive patches. Unlike red light, NB-UVB is UV-based, so it carries the usual cautions about cumulative sun-type exposure.
308 nm Excimer Laser and Lamp
The 308 nm excimer laser delivers targeted UVB to individual patches. It tends to repigment localized vitiligo faster than NB-UVB and spares the surrounding normal skin. It is a strong choice for a few stubborn spots, especially on the face.
Topical Ruxolitinib (Opzelura)
This is the big shift. In July 2022, the U.S. FDA approved ruxolitinib 1.5% cream (Opzelura) for non-segmental vitiligo in patients 12 and older. It is the first drug specifically approved to restore pigment in vitiligo. The approval rested on two phase 3 trials (TRuE-V1 and TRuE-V2) involving 674 patients, published in the New England Journal of Medicine. At week 24, the share of patients reaching 75% facial repigmentation (a measure called F-VASI75) was 29.8% on ruxolitinib versus 7.4% on the inactive cream in one trial, and 30.9% versus 11.4% in the other. Results kept improving through week 52. That is a properly designed, blinded, placebo-controlled body of evidence, which is exactly what red light lacks.
Two things are worth noticing about even this strong evidence. First, the numbers are modest: most people did not hit 75% facial repigmentation in six months, which is a reminder that vitiligo is hard to treat with anything. Second, the trial was rigorous enough to separate the drug's real effect from the placebo response, and the placebo group still showed some repigmentation. That placebo signal is exactly why uncontrolled red light testimonials and before-after photos are so misleading. Some vitiligo repigments on its own, or with sun exposure, or with the passage of time. Without a control group, you cannot tell whether the light did anything.
Topical Steroids and Calcineurin Inhibitors
Topical corticosteroids and calcineurin inhibitors (tacrolimus, pimecrolimus) are long-standing off-label options, often paired with phototherapy. They target the immune side of the disease.
| Treatment | Evidence strength | Typical use | Notes |
|---|---|---|---|
| Topical ruxolitinib (Opzelura) | Strong (2 phase 3 RCTs) | Non-segmental, ≤10% body, face | Only FDA-approved repigmentation drug |
| Narrowband UVB | Strong | Widespread vitiligo | First-line phototherapy; uses UV |
| 308 nm excimer laser | Moderate to strong | Localized patches | Faster on small areas |
| Topical steroids / calcineurin inhibitors | Moderate | Localized, often combined | Standard off-label backbone |
| He-Ne red laser | Weak | Segmental head/neck | Small old studies only |
| Consumer red light panels | Very weak / absent | Marketed broadly | Not supported by direct data |
The takeaway: red light is not in the same evidence tier as the standard options. It sits far below them.
Safety and Side Effects
The safety story is the friendliest part of red light therapy. Because it uses no UV, it does not burn, tan, or carry the long-term skin-aging and skin-cancer concerns tied to UV-based phototherapy. Reported side effects are usually mild, like temporary warmth or redness.
Eye protection still matters. Bright red and near-infrared light can be uncomfortable or potentially harmful to the eyes at close range, so goggles are standard during sessions, especially for facial treatment. People taking medications that increase light sensitivity, or those with a history of light-triggered conditions, should check with a doctor first.
There is also a contrast worth drawing with the standard treatments. NB-UVB and excimer use UV light, which works but adds up over years of exposure and brings the usual UV cautions. Red light skips that tradeoff entirely. So on pure safety, red light is the gentler option. The catch is that "gentle and unproven" is not better than "slightly riskier and proven" when your skin is actively losing color.
The bigger safety issue with red light and vitiligo is not the light. It is the opportunity cost. Chasing an unproven home device can delay a proven treatment during the window when the disease is still active and most treatable. Vitiligo responds best when caught early, while the immune attack is fresh and the pigment-cell reservoirs are intact. Spend a year on a panel that does nothing, and the patches may stabilize into white skin that no treatment can fully reverse. That delay can cost real repigmentation, and it is the most common way people get hurt by an otherwise harmless device.
A note on regulation: red light devices that carry FDA clearance are cleared for specific marketed uses such as wrinkles, pain, or hair growth. Vitiligo is not a cleared indication for consumer red light panels. "FDA cleared" on a box does not mean the device was proven to treat vitiligo.
Who Might Reasonably Consider It
Red light therapy for vitiligo makes the most sense for a small group, and only with eyes open.
A person with stable, localized segmental vitiligo on the head or neck has the closest match to the existing studies, though those studies used a medical He-Ne laser, not a home panel. Anyone considering red light should treat it as an add-on under dermatologist supervision, not a replacement for proven care. It may be reasonable to ask a dermatologist about layering red light onto excimer or NB-UVB, since that is where the most active research is heading.
It is a poor choice as a first or only treatment, especially for spreading non-segmental vitiligo, where the evidence is essentially absent and effective approved options exist. If pigment loss is active or expanding, the priority is seeing a dermatologist quickly, not ordering a panel online.
For more on the science behind these wavelengths and devices, see our explainer on the science of photobiomodulation and our breakdown of red light therapy wavelengths. To understand the broader claims and limits, our guide to what the clinical research actually says about red light therapy and our conditions matrix are useful. For skin-specific uses, see red light therapy for skin.
Frequently Asked Questions
Does red light therapy actually repigment vitiligo?
In a narrow sense, yes, but the proof is thin. Two small studies using a 632.8 nm helium-neon medical laser reported more than 50% repigmentation in about 60% of patients with segmental vitiligo on the head and neck. That is real, but it involved a focused medical laser, a small number of patients, and only one type of vitiligo. There is almost no direct evidence that consumer red light panels or masks repigment vitiligo.
Is red light therapy better than narrowband UVB for vitiligo?
No. Narrowband UVB is one of the best-supported vitiligo treatments and works on widespread disease. Red light therapy has only a few small studies, all in segmental vitiligo, and no large trials. NB-UVB has decades of clinical use behind it. The two are not in the same evidence class.
Can I use a home red light panel to treat my vitiligo?
There is no good evidence that home LED panels treat vitiligo. The studies that showed benefit used a 632.8 nm medical laser, which delivers light very differently from a diffuse LED array. Vitiligo is also not an FDA-cleared use for these consumer devices. If you want to try one, do it as an add-on under a dermatologist's guidance, not as your main treatment.
How long would red light therapy take to show results for vitiligo?
In the laser studies, initial repigmentation appeared after an average of roughly 16 to 17 sessions given once or twice a week, so several weeks to a couple of months before any visible change. Vitiligo repigmentation is slow with any treatment. Results from consumer devices are unstudied, so no reliable timeline exists for them.
Is red light therapy safe for vitiligo-affected skin?
Red light uses no UV, so it does not burn or carry the long-term UV risks of standard phototherapy, and reported side effects are usually mild. Eye protection is recommended. The main risk is not the light itself but using an unproven device instead of an effective treatment while the disease is still active and most treatable.
This article is for general information only and is not medical advice. Vitiligo treatment should be guided by a board-certified dermatologist. Talk to a qualified clinician before starting or changing any treatment.
References
- Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo (Yu et al., J Invest Dermatol 2003)
- Low-energy helium-neon laser therapy induces repigmentation and improves cutaneous microcirculation in segmental-type vitiligo (Wu et al., 2008)
- Mechanisms of repigmentation induced by photobiomodulation therapy in vitiligo (Yu et al., Exp Dermatol 2019)
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo (Rosmarin et al., N Engl J Med 2022)
- FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older (U.S. FDA, 2022)
- PubMed search: photobiomodulation and vitiligo repigmentation
- PubMed search: helium-neon laser and vitiligo
- PubMed search: narrowband UVB and vitiligo repigmentation